The low points of the SP continue to get higher. Without risk of starting to talk charts the fundamentals of ePAT/PainChek continue to progress from the prospectus days. Only real omission that is noteworthy is that of Strenuus insurance (for now).
Aside from that the SP is growing gradually as the milestones are achieved.
Once again fundamentally, PCK could soon see new highs as the company nears the commercialisation stage (proper). The company has never been in a better position and there is no better time to be a shareholder with the infant App and true blue sky just around the corner.
PCK Price at posting:
7.2¢ Sentiment: Buy Disclosure: Held
